Welcome to our dedicated page for Krystal Biotech SEC filings (Ticker: KRYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Krystal Biotech, Inc. (NASDAQ: KRYS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Krystal Biotech is a commercial-stage biotechnology company headquartered in Pittsburgh, Pennsylvania, focused on genetic medicines such as VYJUVEK for dystrophic epidermolysis bullosa and a pipeline of investigational programs in respiratory, ophthalmology, dermatology, oncology, and aesthetics.
Through this page, users can review Form 8‑K current reports in which Krystal Biotech discloses material events. Recent 8‑K filings have covered quarterly financial results, commercial launches of VYJUVEK in new markets such as Japan, regulatory approvals, and key clinical milestones, including updates on trials for KB801 in neurotrophic keratitis and KB304 in aesthetics. These filings often incorporate press releases and slide presentations by reference, providing additional context on the company’s operational and clinical progress.
In addition to 8‑K reports, investors may use this page to navigate to Krystal Biotech’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which contain detailed information on its gene therapy platform, risk factors, financial statements, and segment information related to the development and commercialization of pharmaceutical products. For users interested in governance and compensation matters, proxy statements and related filings can also be accessed.
Stock Titan enhances these documents with AI-powered summaries that explain the key points of lengthy filings, helping readers quickly understand financial results, clinical updates, and regulatory developments without reading every page. Real-time integration with EDGAR ensures that new Krystal Biotech filings, including any future Forms 4 reporting insider transactions, 10‑Q, or 10‑K submissions, appear promptly, while AI-generated highlights point to sections that may be most relevant for KRYS shareholders and analysts.
Krystal Biotech, Inc. reports a full-year Form 10-K describing a commercial-stage gene therapy company that launched its first approved product, VYJUVEK, in the U.S. (2023) and expanded launches to Europe and Japan in 2025. The report highlights $730.3 million in cumulative net product revenue since U.S. launch, global regulatory approvals and an advanced pipeline including inhaled KB407 for cystic fibrosis and inhaled KB707 for NSCLC. The company operates two in‑house CGMP facilities, reports an aggregate market value of common stock held by non-affiliates of $3.5 billion as of June 30, 2025, and had 29,232,189 shares outstanding as of February 11, 2026.
The filing details clinical progress across multiple programs, regulatory designations (ODD, RPDD, RMAT, FDA platform designation), commercialization status, manufacturing scale-up, and known program risks summarized under "Risk Factors."
Krystal Biotech Inc filing shows an amended Schedule 13G/A by The Vanguard Group reporting 0 shares and 0% beneficial ownership as of the filing; the amendment documents an internal realignment effective January 12, 2026 that disaggregated certain Vanguard subsidiaries for SEC reporting. The form is signed on 03/27/2026.
Krystal Biotech EVP Laurent Goux has filed an initial ownership report showing equity awards and stock holdings in Krystal Biotech, Inc. The Form 3 lists several grants of stock options and restricted stock units, plus common shares, all held directly as of March 1, 2026.
Stock option positions include grants covering 9,050, 7,449, 2,367, 4,750, 2,750 and 19,000 shares of common stock. Restricted stock unit awards include 3,628, 891 and 674 units, and he directly holds 919 shares of common stock.
The footnotes state that multiple option and RSU grants vest in four equal annual installments on the first through fourth anniversaries of their grant dates in 2023, 2024, 2025 and 2026, subject to his continued service, and note that one stock option grant for 19,000 shares is fully vested.
Krystal Biotech, Inc. executive vice president and general counsel Thomas John Charles filed an initial ownership report showing his equity interests in the company. This Form 3 does not report any new buy or sell transactions; it lists existing awards and holdings.
He directly holds several stock options, including one with 9,050 shares underlying common stock, and multiple restricted stock unit (RSU) awards, including 3,628 RSUs, along with 642 shares of common stock. Footnotes explain that the options and RSUs generally vest in four equal annual installments beginning around late February in 2024, 2025, and 2026, subject to his continued service, with one option already fully vested.
Krystal Biotech President of R&D and director Suma Krishnan sold 25,000 shares of the company’s common stock on March 4, 2026 in open-market trades under a pre-arranged Rule 10b5-1 trading plan. The reported sales occurred at prices between $256.68 and $266.93 per share.
After these transactions, she directly held 1,403,155 shares of Krystal Biotech common stock. She also had indirect ownership of 90,000 shares through SMK Trust and 50,000 shares through the Krishnan Family Trust, where she and her spouse are joint beneficial owners with joint voting and investment control.
Krystal Biotech, Inc. reported that President and CEO Krishnan Krish sold 25,000 shares of common stock on March 4, 2026 in multiple open‑market transactions. The weighted average sale prices disclosed in the table range from about $257.31 to $266.56 per share.
The footnotes state these sales were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on September 4, 2025, which began on December 4, 2025 and is scheduled to terminate on December 4, 2026 or earlier under its terms. After these sales, Krish directly owned 1,475,253 shares and also had indirect holdings of 90,000 and 50,000 shares through spousal and family trusts.
Krystal Biotech, Inc. Chief Accounting Officer Kathryn Romano reported a mix of stock sales, vesting, and new equity awards. On March 2, 2026, she completed an open-market sale of 750 shares of common stock at $267.60 per share under a pre-arranged Rule 10b5-1 trading plan, leaving 22,366 common shares held directly.
On February 27, 2026, 7,500 performance stock units vested after meeting 2024 performance goals, and 550 restricted stock units vested from a 2025 grant, both converting into common shares. To cover tax withholding on these vestings, 3,262 and 240 common shares, respectively, were surrendered to the company at a reference price of $275.64 per share.
Also on February 27, Romano received new equity incentives: a stock option for 13,575 shares and a new grant of 5,442 restricted stock units, each vesting in four equal annual installments beginning February 27, 2027.